Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
2011

Mutant Cbl Proteins in Blood Disorders

publication Evidence: moderate

Author Information

Author(s): Naramura Mayumi, Nadeau Scott, Mohapatra Bhopal, Ahmad Gulzar, Mukhopadhyay Chandrani, Sattler Martin, Raja Srikumar M, Natarajan Amarnath, Band Vimla, Band Hamid

Primary Institution: University of Nebraska Medical Center

Hypothesis

Loss of normal Cbl functions may lead to unregulated activation of protein tyrosine kinases and cellular transformation.

Conclusion

Mutations in the CBL gene are significant in a subset of myeloid malignancies, suggesting a role in oncogenesis.

Supporting Evidence

  • Mutations in CBL are frequently observed in myelodysplastic syndromes-myeloproliferative neoplasms.
  • Most CBL mutations are missense mutations or small deletions.
  • Wild-type CBL allele is often lost in leukemic clones, replaced by the mutant allele.

Takeaway

Some proteins that help control cell growth can become mutated, leading to blood cancers. Understanding these mutations can help find new treatments.

Methodology

The article reviews functions of Cbl proteins and their mutations in patients and animal models.

Participant Demographics

The study discusses findings in human patients with myeloid malignancies.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication